FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mary Pat Knadler

Research Profile

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Interactions

Procedures

Disorders

Co-author Network

Publications

TOP 3
Lorrene A Buckley; Philip W Iversen; Mary Pat Knadler; Atsushi Sanbuissho; James J Starling; Joseph A Jakubowski
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.
Christine Y Yu; Baojin Zhu; David S Small; Craig A Sponseller; Stuart E Campbell; Thomas L Hunt; Mary Pat Knadler; Roger E Morgan
Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.
Mary Pat Knadler; Evelyn D Lobo; Jill Chappell; RF Bergstrom
Duloxetine: clinical pharmacokinetics and drug interactions.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mary Pat Knadler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Lorrene A Buckley; Philip W Iversen; Mary Pat Knadler; Atsushi Sanbuissho; James J Starling; Joseph A Jakubowski
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.
International journal of toxicology 2012;31(4):317-25.
2012: Christine Y Yu; Baojin Zhu; David S Small; Craig A Sponseller; Stuart E Campbell; Thomas L Hunt; Mary Pat Knadler; Roger E Morgan
Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.
Current medical research and opinion 2012;28(2):187-94.
2011: Mary Pat Knadler; Evelyn D Lobo; Jill Chappell; RF Bergstrom
Duloxetine: clinical pharmacokinetics and drug interactions.
Clinical pharmacokinetics 2011;50(5):281-94.
2010: Shelby Anderson; Mary Pat Knadler; Debra Luffer-Atlas
Overview of metabolite safety testing from an industry perspective.
Bioanalysis 2010;2(7):1249-61.
2010: Evelyn D Lobo; Michael Heathman; Han-Yi Kuan; Shobha Reddy; Lisa O'Brien; Celedon Gonzales; Michael Skinner; Mary Pat Knadler
Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Clinical pharmacokinetics 2010;49(5):311-21.
2009: Jill Chappell; Jingsong He; Mary Pat Knadler; Malcolm Mitchell; Douglas Lee; Evelyn Lobo
Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.
Journal of clinical pharmacology 2009;49(12):1456-66.
2009: Shelby Anderson; Debra Luffer-Atlas; Mary Pat Knadler
Predicting circulating human metabolites: how good are we?
Chemical research in toxicology 2009;22(2):243-56.
2009: Evelyn D Lobo; Tonya Quinlan; Lisa O'Brien; Mary Pat Knadler; Michael Heathman
Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.
Clinical pharmacokinetics 2009;48(3):189-97.
2008: Joachim F Wernicke; Beth Pangallo; Fujun Wang; Isabelle Murray; Judith W Henck; Mary Pat Knadler; Deborah N D'Souza; Jack P Uetrecht
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
Current drug safety 2008;3(2):132-42.
2008: Evelyn D Lobo; RF Bergstrom; Shobha Reddy; Tonya Quinlan; Jill Chappell; Quan Hong; Barbara Ring; Mary Pat Knadler
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Clinical pharmacokinetics 2008;47(3):191-202.
2008: Evelyn D Lobo; Corina Loghin; Mary Pat Knadler; Tonya Quinlan; Lu Zhang; Jill Chappell; Richard Lucas; RF Bergstrom
Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.
Clinical pharmacokinetics 2008;47(2):103-9.
2007: Darlene K Satonin; Julie D McCulloch; Fengjiun Kuo; Mary Pat Knadler
Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;852(1-2):582-9.
2007: Lu Zhang; Jill Chappell; Celedon R Gonzales; David Small; Mary Pat Knadler; J T Callaghan; Jennie L Francis; Durisala Desaiah; Mark Leibowitz; Larry Ereshefsky; David Hoelscher; Philip T Leese; Michael Derby
QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
Journal of cardiovascular pharmacology 2007;49(3):146-53.
2007: Clark Chan; Kwee Poo Yeo; Alan X Pan; Maggie Lim; Mary Pat Knadler; David S Small
Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects.
British journal of clinical pharmacology 2007;63(3):310-4.
2007: Si Tianmei; Mary Pat Knadler; Ming T Lim; Kwee Poo Yeo; Leyan Teng; Shu Liang; Alan X Pan; Evelyn D Lobo
Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Clinical pharmacokinetics 2007;46(9):767-75.
2005: A Suri; S Reddy; C Gonzales; Mary Pat Knadler; R A Branch; Michael H Skinner
Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.
International journal of clinical pharmacology and therapeutics 2005;43(2):78-84.
2005: Frank P Bymaster; Thomas C Lee; Mary Pat Knadler; Michael Detke; Smriti Iyengar
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Current pharmaceutical design 2005;11(12):1475-93.
2004: Teng C Hua; Alan Pan; Clark Chan; Yeo K Poo; Michael H Skinner; Mary Pat Knadler; Celedon R Gonzales; Stephen D Wise
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
British journal of clinical pharmacology 2004;57(5):652-6.
2004: Michael H Skinner; Han-Yi Kuan; Andrej Skerjanec; Mary E Seger; Michael Heathman; Lisa O'Brien; Shobha Reddy; Mary Pat Knadler
Effect of age on the pharmacokinetics of duloxetine in women.
British journal of clinical pharmacology 2004;57(1):54-61.
2003: R J Lantz; Todd A Gillespie; T James Rash; Fengjiun Kuo; M Skinner; Han-Yi Kuan; Mary Pat Knadler
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1142-50.
2003: Michael H Skinner; Han-Yi Kuan; Alan Pan; Korbtham Sathirakul; Mary Pat Knadler; Celedon R Gonzales; Kwee Poo Yeo; Shobha Reddy; Maggie Lim; Mosun Ayan-Oshodi; Stephen D Wise
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Clinical pharmacology and therapeutics 2003;73(3):170-7.
2001: J W Miller; Andrej Skerjanec; Mary Pat Knadler; A Ghosh; S R Allerheiligen
Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.
Pharmaceutical research 2001;18(7):1024-8.